Abstract 1674P
Background
Nasopharyngeal carcinoma (NPC) can have implications on the sexual health of patients suffering from this cancer. This can be affected by various factors, whether it be the cancer itself, the treatments administered, or the associated psychological stress. However, sexual disorders are often overlooked in the management of these patients. The aim: is to assess the sexual health of patients with NPC at different stages of their treatment.
Methods
This is a descriptive analytical study evaluating sexual health in adult patients with NPC using EORTC SHQ-C22 Questionnaire. Thirty married patients were included between September and December 2023. The mean age was 45 years [32-68] with a sex ratio of 4 (24/6). Tumor stage (III) was the most represented (25 patients; 83.3%). The questionnaire was translated into colloquial Arabic and administered during treatment for 27 patients (71.4%), and within the first 6 months of follow-up for 3 patients. All patients resided at home with their spouses at the time of the questionnaire.
Results
According to the EORTC SHQ-C22 scale, 17 patients were not sexually active (not at all or a little) during treatment (56.6%) with a feeling of sexual satisfaction (often or quite often) in 17 patients (70.8%). Thirteen patients (43.3%) considered sexual activity to be enjoyable (often or quite often). A negative impact of fatigue and treatment on sexual activity was experienced by 14 patients (46.6%, often or quite often) and a feeling of inability to satisfy their partner was felt by 12 patients (7% a little, 10% often, and 73% quite often). Sexual activity was not painful for 26 patients (86.6%), and concerns about pain during sexual intercourse or intimate physical contact were not felt by 21 patients (70%). Discussion with a doctor about sexuality was absent in most cases (27 patients, 90%). Communication with the partner about sexuality was unsatisfactory in all patients (90% did not communicate and 10% communicated very little). The median score of the EORTC SHQ-C22 was 67 [30-75]. Among these patients, 7 patients (23.3%) wished to receive treatment for their sexuality, and no patient was using any specific sexual treatment.
Conclusions
The search for sexual disorders in patients with NPC is essential, for better quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut National d'Oncologie Rabat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1687P - Perceptions of genetic testing and lived experiences in women with locally advanced or metastatic ovarian cancer: A focus on BRCAm and BRCAwt patients
Presenter: María Jesús Rubio Pérez
Session: Poster session 11
1688P - Psychosocial distress and spirituality among elderly patients with cancer in Nigeria
Presenter: Zainab Ogunjimi
Session: Poster session 11
1689TiP - The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
Presenter: Domenico Galetta
Session: Poster session 11
1692P - A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002/ BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced renal cell carcinoma
Presenter: Xinan Sheng
Session: Poster session 11
1693P - CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster session 11
1695P - Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Presenter: Ulka Vaishampayan
Session: Poster session 11
1696P - A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results
Presenter: Saby George
Session: Poster session 11
1697P - Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
Presenter: Sarmad Sadeghi
Session: Poster session 11
1698P - Avelumab + axitinib (Ave + Axi) vs sunitinib (Sun) in advanced renal cell carcinoma (aRCC): Final analysis of patient (pt)-reported outcomes (PROs) and quality-adjusted time without symptoms or toxicity (Q-TWiST)
Presenter: Balaji Venugopal
Session: Poster session 11